New Delhi: The demand for Indian generic drugs has shot up in China amid the massive COVID surge in the country, with Chinese experts cautioning that fake versions of these drugs are flooding the market.

China's National Health Security Administration said on Sunday that Pfizer's Paxlovid oral medication, which is used to treat COVID-19, could not be included in the "register of drugs in the basic medical insurance", because the company's quotation was too high, media reports said.

Due to the massive shortage of Paxlovid, demand for Indian generic versions has gone up through Chinese e-commerce platforms.

Click for more articles on China

"On the Chinese e-commerce platforms, at least the following four generic COVID drugs produced in India have been listed for sale in recent weeks:

- Primovir,

- Paxista,

- Molnunat,

- Molnatris.

"Primovir and Paxista are both generic versions of Paxlovid, while the other two are generic versions of Molnipiravir," Chinese media outlet Sixth Tone reported.

According to the report, all four drugs appear to have been approved for emergency use by Indian authorities but are not legal for use in China.

He Xiaobing, the head of Beijing Memorial Pharmaceutical, told Sixth Tone that India was "the only country where we can source reliable and affordable COVID drugs with guaranteed therapeutic effects".

"But the strong demand was used by illegal groups that produce counterfeit drugs." "This will badly affect patients' treatment," he said.

China's health system, which caters to 1.4 billion people, is under strain, especially due to the heavy costs of drug supply, which are controlled by multinational pharmaceutical giants.

India has been persuading China to permit its pharma products to reduce costs for its citizens and to decrease the massive trade deficit between the two countries.

At one time, Indian cancer drugs have become very famous for their efficacy and affordability.

Considering their popularity, a Chinese film by the name of "Dying to Survive" showing the survival of cancer patients on the banned imported Indian drugs had a successful run in China.

NPPA may fix retail price of drugs under phase IV Clinical trials

Govt Job: For the post of Director at CDTL, CDSCO

List of approved FDCs (Fixed Dose Combinations) Updated

List of approved New Drugs Updated

NPPA extends ceiling price of LMO, Oxygen Inhalation

Drug recall: Daptomycin for Injection recalled due to this reason

New BCG vaccine for TB: Clinical trials to start soon

Drug licences of these two firms suspended: FDA Manipur

Fake pharma firm busted, two arrested

Latest Notifications regarding Pharmaceutical
https://thehealthmaster.com/2023/01/09/high-demand-for-indian-generic-drugs-in-china/